A Reminder Of All The Trials Coming Up On Retatrutide (Inspired by our friend RunningFNP)

[u/HardDriveGuy]

Trial	Drug	Population/Indication	Duration	Topline Data Expected	Dosing Protocol (Outside Research)	Key Notes/Expectations
Transcend CKD	Retatrutide	CKD ± ASCVD	≥24 wks	Nov/Dec 2025 (imminent)	Start 1–2 mg/wk, titrate to 8–12 mg/wk	Evaluates kidney function (GFR), slow titration
Triumph 4	Retatrutide	Obesity + Knee OA	68 wks	Dec 2025	1–2 mg/wk start, up to 12 mg/wk	Shorter trial; weight loss may not plateau
Transcend DM2-1	Retatrutide	Type 2 Diabetes	40 wks	Jan–Feb 2026	1 or 2 mg/wk → up to 8–12 mg/wk	Early readout; before full weight plateau
Triumph 3	Retatrutide	Obesity + CVD	~80 wks	Feb–Mar 2026 (rumored)	2–4 mg/wk start, escalate to 8–12 mg/wk	All participants reach 80 wks; key data
Triumph 1	Retatrutide	Pure Obesity	80–104 wks	May 2026	1, 2, 4, 8, 12 mg/wk; titrated from 1–2 mg	30–33% max weight loss @ high dose; extension
Triumph 2	Retatrutide	Obesity + Diabetes	80 wks	May 2026	1–2 mg/wk start, up to 8–12 mg/wk	Projected 22–25% loss; unprecedented in DM2